WallStSmart

IQVIA Holdings Inc (IQV)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 118% more annual revenue ($35.48B vs $16.31B). MDT leads profitability with a 13.0% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued
MDTSignificantly Overvalued (-260.2%)

Margin of Safety

-260.2%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$112.84B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

IQV carries more volatility with a beta of 1.41 — expect wider price swings.

IQV is growing revenue faster at 10.3% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IQV scores higher overall (72/100 vs 56/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?